ey0015.9-11 | Biologic agents in chronic inflammatory diseases: lights and shadows | ESPEYB15
A Assa
, M Amitai
, ML Greer
, DA Castro
, RC Kuint
, M Martínez-León
, I Herman-Sucharska
, E Coppenrath
, S Anupindi
, A Towbin
, D Moote
, O Konen
, LT Pratt
, A Griffiths
, D Turner
, ImageKids Study Group
To read the full abstract: J Pediatr Gastroenterol Nutr. 2017;65:293-298Growth deceleration and impaired pubertal growth spurt are common concerns in patients with early onset inflammatory bowel disease (IBD) (1-2). Previous studies confirmed the efficacy and safety of infliximab, an anti-tumor necrosis factor alpha (TNF-α) antibody, in achieving clinical remission in luminal Crohn...